Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator.

Abstract:

:We analyzed a list of the top 100 bestselling drugs as a struggling market for new FDA approvals. Using the time from drug approval by the FDA as a measure of drug age, our analysis showed that the top 100 bestselling drugs are getting older. This reflects the stalled launch of new drugs into the market during recent years.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Polanski J,Bogocz J,Tkocz A

doi

10.1016/j.drudis.2015.06.015

subject

Has Abstract

pub_date

2015-11-01 00:00:00

pages

1300-4

issue

11

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(15)00266-4

journal_volume

20

pub_type

杂志文章
  • Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor.

    abstract::The pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) are ligand-activated nuclear receptors (NRs) that are notorious for their role in drug metabolism, causing unintended drug-drug interactions and decreasing drug efficacy. They control the xenobiotic detoxification system by regulating the exp...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.01.021

    authors: Chai SC,Lin W,Li Y,Chen T

    更新日期:2019-03-01 00:00:00

  • Ligand-mediated active targeting for enhanced oral absorption.

    abstract::Although the oral route is the most popular and acceptable way of drug administration owing to good patient compliance and safety, oral drug delivery is faced with continuous challenges regarding poorly soluble, poorly permeable or gastrointestinally unstable drugs such as proteins and polypeptides. The overall bioava...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.03.001

    authors: Zhang X,Wu W

    更新日期:2014-07-01 00:00:00

  • HCV E2 core structures and mAbs: something is still missing.

    abstract::The lack of structural information on hepatitis C virus (HCV) surface proteins has so far hampered the development of effective vaccines. Recently, two crystallographic structures have described the core portion (E2c) of E2 surface glycoprotein, the primary mediator of HCV entry. Despite the importance of these studie...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.08.011

    authors: Castelli M,Clementi N,Sautto GA,Pfaff J,Kahle KM,Barnes T,Doranz BJ,Dal Peraro M,Clementi M,Burioni R,Mancini N

    更新日期:2014-12-01 00:00:00

  • Moving forward in clinical trials for ALS: motor neurons lead the way please.

    abstract::Amyotrophic lateral sclerosis (ALS) is one of the most complex motor neuron diseases. Even though scientific discoveries are accelerating with an unprecedented pace, to date more than 30 clinical trials have ended with failure and staggering frustration. There are too many compounds that increase life span in mice, bu...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.10.014

    authors: Genç B,Özdinler PH

    更新日期:2014-04-01 00:00:00

  • Model fluids representing aqueous in-vitro diagnostic reagents for the development of dispensing systems.

    abstract::Analyzers for in-vitro diagnostic (IVD) testing facilitate the determination of medical information from biological samples. To reach a high quality, the detection reagents have to be dispensed with a high degree of precision and accuracy. A technology change from conventional pipetting systems to contact-free dispens...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2013.06.011

    authors: Losleben N,Spinke J,Adler S,Oranth N,Zengerle R

    更新日期:2013-11-01 00:00:00

  • Ophthalmic light sensitive nanocarrier systems.

    abstract::The eye is afflicted by chronic vision debilitating neovascular disorders, such as age-related macular degeneration, proliferative diabetic retinopathy, and corneal angiogenesis. Photodynamic therapy (PDT) is an innovative, evolving approach for treating neovascular diseases of the eye. PDT refers to the process of ac...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.12.005

    authors: Christie JG,Kompella UB

    更新日期:2008-02-01 00:00:00

  • Miniaturized HTS technologies - uHTS.

    abstract::The transition from slow, manual, low-throughput screening to industrialized robotic ultra-high throughput screening (uHTS) in the past few years has made it possible to screen hundreds of thousands of chemical entities against a biological target in a short time-frame. The need to minimize the cost of screening has b...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01807-4

    authors: Wölcke J,Ullmann D

    更新日期:2001-06-01 00:00:00

  • Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats.

    abstract::In therapeutic areas aimed at developing an orally administered drug, the pharmacokinetic profile of a drug candidate after oral administration in vivo is pivotal in evaluating its success. This can be done by monitoring the plasma concentration versus time after dosing and calculating the area under the curve (AUC). ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(98)01299-9

    authors: Cox KA,Dunn-Meynell K,Korfmacher WA,Broske L,Nomeir AA,Lin CC,Cayen MN,Barr WH

    更新日期:1999-05-01 00:00:00

  • Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development.

    abstract::Drug-delivery technologies for modified drug release have been in existence for decades, but their utilization has been largely limited to post-launch efforts improving therapeutic outcomes. Recently, they have gained renewed importance because the pharmaceutical industry is steadily shifting to a more integrated disc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.12.008

    authors: Yang W,Bhattachar SN,Patel PJ,Landis M,Patel D,Reid DL,Duvnjak Romic M

    更新日期:2020-12-14 00:00:00

  • Bispecific antibodies.

    abstract::Bispecific antibodies (bsAbs) combine specificities of two antibodies and simultaneously address different antigens or epitopes. BsAbs with 'two-target' functionality can interfere with multiple surface receptors or ligands associated, for example with cancer, proliferation or inflammatory processes. BsAbs can also pl...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.02.008

    authors: Kontermann RE,Brinkmann U

    更新日期:2015-07-01 00:00:00

  • Importance of target-mediated drug disposition for small molecules.

    abstract::Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situatio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.06.010

    authors: Smith DA,van Waterschoot RAB,Parrott NJ,Olivares-Morales A,Lavé T,Rowland M

    更新日期:2018-12-01 00:00:00

  • Cell microarrays in drug discovery.

    abstract::There is an increasing need for systematic cell-based assays in a high-throughput screening (HTS) format to analyze the phenotypic consequences of perturbing mammalian cells with drugs, genes, interfering RNA. Taking advantage of the recent progress in microtechnology, new cell microarrays are being developed and appl...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.05.015

    authors: Castel D,Pitaval A,Debily MA,Gidrol X

    更新日期:2006-07-01 00:00:00

  • Gestational hypoxia and epigenetic programming of brain development disorders.

    abstract::Adverse environmental conditions faced by an individual early during its life, such as gestational hypoxia, can have a profound influence on the risk of diseases, such as neurological disorders, in later life. Clinical and preclinical studies suggest that epigenetic programming of gene expression patterns in response ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.09.010

    authors: Ma Q,Xiong F,Zhang L

    更新日期:2014-12-01 00:00:00

  • Humans are animals, but are animals human enough? A systematic review and meta-analysis on interspecies differences in renal drug clearance.

    abstract::Various animal models are used to study pharmacokinetics (PK) of drugs in development. Human renal clearance (CLr) should be predictable through interpolation from animal data by allometric scaling. Based on this premise, we quantified interspecies differences in CLr, and related them to drug properties. Using PubMed ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.01.018

    authors: Jansen K,Pou Casellas C,Groenink L,Wever KE,Masereeuw R

    更新日期:2020-04-01 00:00:00

  • Opportunities for novel therapeutic agents acting at chemokine receptors.

    abstract::Chemokines are proinflammatory mediators that primarily control leukocyte migration into selected tissues and upregulation of adhesion receptors. They also have a role in pathological conditions that require neovascularization and are implicated in the suppression of viral replication. By interaction with their respec...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(98)01280-x

    authors: Saunders J,Tarby CM

    更新日期:1999-02-01 00:00:00

  • Rational drug discovery: what can we learn from regulatory networks?

    abstract::To enable the list of genes and proteins contained within genomic databases to be useful for drug discovery, we need to understand how the genome maps into the phenome. An essential, but not explicitly listed ingredient of the genome is the regulatory interactions between genes and proteins that form a genome-wide net...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02463-7

    authors: Huang S

    更新日期:2002-10-15 00:00:00

  • Designed covalent allosteric modulators: an emerging paradigm in drug discovery.

    abstract::Covalent allosteric modulators possess the pharmacological advantages (high potency, extended duration of action and low drug resistance) of covalent ligands and the additional benefit of the higher specificity and lower toxicity of allosteric modulators. This approach is gaining increasing recognition as a valuable t...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.11.013

    authors: Lu S,Zhang J

    更新日期:2017-02-01 00:00:00

  • Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents.

    abstract::Recently, remarkable efforts have focused on research towards enhancing and delivering efficacious and advanced therapeutic agents. Even though this involves significant challenges, innovative techniques and materials have been explored to overcome these. The advantageous properties of mesoporous silica nanoparticles ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.06.006

    authors: Alyassin Y,Sayed EG,Mehta P,Ruparelia K,Arshad MS,Rasekh M,Shepherd J,Kucuk I,Wilson PB,Singh N,Chang MW,Fatouros DG,Ahmad Z

    更新日期:2020-08-01 00:00:00

  • Driving external chemistry optimization via operations management principles.

    abstract::Confronted with the need to significantly raise the productivity of remotely located chemistry CROs Pfizer embraced a commitment to continuous improvement which leveraged the tools from both Lean Six Sigma and queue management theory to deliver positive measurable outcomes. During 2012 cycle times were reduced by 48% ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.07.017

    authors: Bi FC,Frost HN,Ling X,Perry DA,Sakata SK,Bailey S,Fobian YM,Sloan L,Wood A

    更新日期:2014-03-01 00:00:00

  • Value your compound management team!

    abstract::The Discussion Forum provides a medium for airing your views on any issues related to the pharmaceutical industry and obtaining feedback and discussion on these views from others in the field. You can discuss issues that get you hot under the collar, practical problems at the bench, recently published literature, or j...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01816-5

    authors: Ray BJ

    更新日期:2001-06-01 00:00:00

  • Multiple active receptor conformation, agonist efficacy and maximum effect of the system: the conformation-based operational model of agonism.

    abstract::The operational model of agonism assumes that the maximum effect a particular receptor system can achieve (the Em parameter) is fixed. Em estimates are above but close to the asymptotic maximum effects of endogenous agonists. The concept of Em is contradicted by superagonists and those positive allosteric modulators t...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2012.12.004

    authors: Roche D,Gil D,Giraldo J

    更新日期:2013-04-01 00:00:00

  • KDI tripeptide from laminin: a novel approach to treat neurodegenerative disorders.

    abstract::The excessive release of glutamate following brain injury is responsible for the phenomenon of glutamate excitotoxicity, mediated through glutamate receptors, resulting in apoptotic cell death. KDI ameliorates excitotoxicity and regenerates damaged nerve cells. ...

    journal_title:Drug discovery today

    pub_type: 新闻

    doi:10.1016/S1359-6446(05)03617-2

    authors: Carney S

    更新日期:2005-10-01 00:00:00

  • The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

    abstract::Lack of predictability of clinical efficacy and safety is an important problem facing pharmaceutical research today. Translational PK-PD has the ability to integrate data generated from diverse test platforms during discovery and development in a mechanistic framework. Therefore, successful implementation of translati...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.10.002

    authors: Agoram BM,Martin SW,van der Graaf PH

    更新日期:2007-12-01 00:00:00

  • Knowledge-based chemoinformatic approaches to drug discovery.

    abstract::The modern drug discovery process is steadily becoming more information driven. Structural, physicochemical and ADME-Tox property profiles of reference (successful) ligands, along with structural information of their target proteins, have been extremely useful for early-stage drug discovery. Recently, databases of kno...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.10.012

    authors: Ghose AK,Herbertz T,Salvino JM,Mallamo JP

    更新日期:2006-12-01 00:00:00

  • Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives.

    abstract::Opinions about the therapeutic efficacy of medicinal herbs differ significantly. Some reported herbal efficacies at low doses of active ingredients suggest a need for investigating whether these are because of placebo or multi-ingredient synergistic effects. This review discusses the opinions, methods and outcomes of ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.03.012

    authors: Ma XH,Zheng CJ,Han LY,Xie B,Jia J,Cao ZW,Li YX,Chen YZ

    更新日期:2009-06-01 00:00:00

  • Thrombosis, platelets, microparticles and PAH: more than a clot.

    abstract::Pulmonary arterial hypertension (PAH) is a progressive disease that involves pathological remodeling, vasoconstriction and thrombosis. Alterations in hemostasis, coagulation and platelet activation are consistently observed in PAH patients. Microparticles derived from platelets, inflammatory cells and the endothelium ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.04.001

    authors: Lannan KL,Phipps RP,White RJ

    更新日期:2014-08-01 00:00:00

  • Preparing for the new millennium.

    abstract::Since being introduced to the field of drug discovery at Zeneca Pharmaceuticals in 1991, it has become apparent to me that a blizzard of revolutionary novel approaches has swept through the pharmaceutical industry. Now, the discovery process has become completely transformed and the race to develop commercially succes...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(98)01289-6

    authors: Tranter D

    更新日期:1999-01-01 00:00:00

  • Cancer cell senescence: a new frontier in drug development.

    abstract::Senescence forms a universal block to tumorigenesis which impacts on all hallmarks of cancer, making it an attractive target for drug discovery. Therefore a strategy must be devised to focus this broad potential into a manageable drug discovery programme. Several issues remain to be addressed including the lack of rob...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.01.019

    authors: Cairney CJ,Bilsland AE,Evans TR,Roffey J,Bennett DC,Narita M,Torrance CJ,Keith WN

    更新日期:2012-03-01 00:00:00

  • Enantioselective chromatography in drug discovery.

    abstract::Molecular chirality is a fundamental consideration in drug discovery, one necessary to understand and describe biological targets as well as to design effective pharmaceutical agents. Enantioselective chromatography has played an increasing role not only as an analytical tool for chiral analyses, but also as a prepara...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03407-0

    authors: Zhang Y,Wu DR,Wang-Iverson DB,Tymiak AA

    更新日期:2005-04-15 00:00:00

  • Is the oral route possible for peptide and protein drug delivery?

    abstract::Oral delivery of peptides and proteins remains an attractive alternative to parenteral delivery and has challenged various attempts at delivery development. Incorporation of new tools into the delivery systems that can raise membrane permeability of macromolecules is essential to attain high oral bioavailability that ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.08.005

    authors: Morishita M,Peppas NA

    更新日期:2006-10-01 00:00:00